• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In

What’s the Latest Progress with Meaningful Use?

Home / News / What’s the Latest Progress with Meaningful Use?

Genelex Blog

What's the Latest Progress with Meaningful Use?

This is a big year for the healthcare world and with the requirements for Meaningful Use scheduled to shift from focusing on initial adoption to focusing on more common use, many people are taking this opportunity to take stock and plan their next moves.

Electronic healthcare records (EHRs) and clinical decision support tools (such as YouScript®) saw widespread adoption in 2013 as many providers sought to meet the March 31, 2014 Meaningful Use Stage 1 deadline. Here are the numbers:

As of the end of 2013, 90% of eligible hospitals and roughly 60% of Medicare- and Medicaid-eligible professionals had committed to an EHR; roughly 441,000 eligible hospitals and professionals had registered for meaningful use; and over 334,000 have received financial incentives for successfully meeting meaningful use requirements.

The Centers for Medicare & Medicaid Services also released more detailed data on what specific requirements and objectives professionals had been hitting. In particular, as of 2013:

  • 97.7% of eligible professionals provided electronic copies of health information;
  • 83.5% of eligible hospitals maintained a computerized provider order entry system;
  • 97.2% of professionals and 98% of hospitals kept an active patient medication list;
  • 96.6% of professionals and 98.1% of hospitals maintained a medication allergy list; and
  • 92.6% provided active medication reconciliation lists

As we move into 2014, the requirements for meaningful use are changing. Stage 2 focuses on: more rigorous health information exchange; increased requirements for e-prescribing and incorporating lab results; electronic transmission of patient care summaries across multiple settings; and more patient-controlled data. About 20% of physicians who participated in meaningful use had already adopted some of the Stage 2 objectives. Overall payment amounts change based on which year providers start implementing these changes, so early adoption is in the provider’s benefit.

However, there have been concerns about the program’s structure, particularly the complexity of the requirements and the responsibilities of EHR vendors. Some vendors have been slow to test their EHR systems for Stage 2 use, which can delay implementation. Providers are hoping that they can push for more flexibility; otherwise some physicians might need to drop out of the program. It will be interesting to see where the industry falls in the coming year.

Stage 3 meaningful use requirements will take effect in 2016 and focus on improved outcomes.

For more information, check out the articles here and here.

Genelex Resources

Affected Conditions
Affected Drugs
Info for Providers
Frequently Asked Questions
Contact Genelex
Join Our Mailing List

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.